Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

BMC Ophthalmology201212:9

DOI: 10.1186/1471-2415-12-9

Received: 14 September 2011

Accepted: 18 May 2012

Published: 18 May 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
14 Sep 2011 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
6 Nov 2011 Reviewed Reviewer Report - Teresa Rolle
8 Nov 2011 Reviewed Reviewer Report - Randy Craven
14 Nov 2011 Reviewed Reviewer Report - Marcelo Hatanaka
31 Jan 2012 Author responded Author comments - David Eveleth
Resubmission - Version 3
31 Jan 2012 Submitted Manuscript version 3
12 Feb 2012 Reviewed Reviewer Report - Teresa Rolle
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
18 May 2012 Editorially accepted
18 May 2012 Article published 10.1186/1471-2415-12-9

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Pfizer Inc
(2)
Pfizer Ltd, Walton-on-the Hill
(3)
Pfizer Inc
(4)
Specialty Care Business Unit La Jolla Laboratories Pfizer Inc

Advertisement